Brought to you by 
Kos, Quintiles market Advicor and Niaspan
30 Jan 2023
Executive Summary
Quintile Transnational's (CRO) marketing unit Innovex will assist with the US commercialization of Kos Pharmaceuticals' (drug delivery) lead products, Niaspan and Advicor, for the treatment of cholesterol disorders.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Kos, Quintiles market Advicor and Niaspan
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice